Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy

References

• ShawTECurrieGPKoudelkaCWSimpsonELEczema prevalence in the United States: data from the 2003 National Survey of Children’s HealthJ Invest Dermatol20111311 67 7320739951
   PubMed Web of Science ®Google Scholar
• OdhiamboJAWilliamsHCClaytonTORobertsonCFAsherMIISAAC Phase Three Study GroupGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase ThreeJ Allergy Clin Immunol20091246 1251 1258.e2320004783
   PubMed Web of Science ®Google Scholar
• BosJDBrenninkmeijerEESchramMEMiddelkamp-HupMASpulsPISmittJHAtopic eczema or atopiform dermatitisExp Dermatol2010194 325 33120100192
   PubMed Web of Science ®Google Scholar
• BieberTAtopic dermatitisAnn Dermatol2010222 125 13720548901
   PubMed Web of Science ®Google Scholar
• MalajianDGuttman-YasskyENew pathogenic and therapeutic paradigms in atopic dermatitisCytokine2015732 311 31825542094
   PubMed Web of Science ®Google Scholar
• LeungDYGuttman-YasskyEDeciphering the complexities of atopic dermatitis: shifting paradigms in treatment approachesJ Allergy Clin Immunol20141344 769 77925282559
   PubMed Web of Science ®Google Scholar
• RomagnaniSThe increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?Immunology20041123 352 36315196202
   PubMed Web of Science ®Google Scholar
• GarnHRenzHEpidemiological and immunological evidence for the hygiene hypothesisImmunobiology20072126 441 45217544829
   PubMed Web of Science ®Google Scholar
• GittlerJKKruegerJGGuttman-YasskyEAtopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitisJ Allergy Clin Immunol20131312 300 31322939651
   PubMed Web of Science ®Google Scholar
• SeidenariSGiustiGObjective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skinActa Derm Venereol1995756 429 4338651017
   PubMed Web of Science ®Google Scholar
• Guttman-YasskyESuárez-FariñasMChiricozziABroad defects in epidermal cornification in atopic dermatitis identified through genomic analysisJ Allergy Clin Immunol20091246 1235 1244.e5820004782
   PubMed Web of Science ®Google Scholar
• Guttman-YasskyEKruegerJGPsoriasis: evolution of pathogenic concepts and new therapies through phases of translational researchBr J Dermatol20071576 1103 111517714560
   PubMed Web of Science ®Google Scholar
• Suárez-FariñasMTintleSJShemerANonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalitiesJ Allergy Clin Immunol20111274 954 964 e1 e421388663
   PubMed Web of Science ®Google Scholar
• BoguniewiczMLeungDYAtopic dermatitis: a disease of altered skin barrier and immune dysregulationImmunol Rev20112421 233 24621682749
   PubMed Web of Science ®Google Scholar
• FujitaHThe role of IL-22 and Th22 cells in human skin diseasesJ Dermatol Sci2013721 3 823746568
   PubMed Web of Science ®Google Scholar
• NogralesKEZabaLCShemerAIL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cellsJ Allergy Clin Immunol20091236 1244 1252.e219439349
   PubMed Web of Science ®Google Scholar
• ZhengYDanilenkoDMValdezPInterleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosisNature20074457128 648 65117187052
   PubMed Web of Science ®Google Scholar
• KaminishiKSomaYKawaYMizoguchiMFlow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mono-nuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the diseaseJ Dermatol Sci2002291 19 2512007717
   PubMed Web of Science ®Google Scholar
• AkkocTde KoningPJRückertBBarlanIAkdisMAkdisCAIncreased activation-induced cell death of high IFN-gammaproducing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseasesJ Allergy Clin Immunol20081213 652 658.e118328893
   PubMed Web of Science ®Google Scholar
• Suárez-FariñasMDhingraNGittlerJIntrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitisJ Allergy Clin Immunol20131322 361 37023777851
   PubMed Web of Science ®Google Scholar
• FlohrCMannJNew insights into the epidemiology of childhood atopic dermatitisAllergy2014691 3 1624417229
   PubMed Web of Science ®Google Scholar
• GooderhamMLyndeCWPappKReview of systemic treatment options for adult atopic dermatitisJ Cutan Med Surg2017211 31 3927635033
   PubMed Web of Science ®Google Scholar
• BieberTAtopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicineAllergy20126712 1475 148223106343
   PubMed Web of Science ®Google Scholar
• D’ErmeAMWilsmann-TheisDWagenpfeilJIL-36γ (IL-1F9) is a biomarker for psoriasis skin lesionsJ Invest Dermatol20151354 1025 103225525775
   PubMed Web of Science ®Google Scholar
• HelloMAubertHBernierCNéelABarbarotSAtopic dermatitis of the adultRev Med Interne2016372 91 9926617291
   PubMed Web of Science ®Google Scholar
• BieberTD’ErmeAMAkdisCClinical phenotypes and endophenotypes of atopic dermatitis: Where are we and where should we go?J Alllergy Clin Immunol20171394S S58 S64
   PubMed Web of Science ®Google Scholar
• BieberTAkdisCLauenerRGlobal Allergy Forum and 3rd Davos Declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicineAllergy2016715 588 59227023268
   PubMed Web of Science ®Google Scholar
• MansouriYGuttman-YasskyEImmune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeuticsJ Clin Med201545 858 87326239452
   PubMed Web of Science ®Google Scholar
• WollenbergAOranjeADeleuranMEuropean Task Force on Atopic Dermatitis/EADV Eczema Task ForceETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patientsJ Eur Acad Dermatol Venereol2016305 729 74727004560
   PubMed Web of Science ®Google Scholar
• RingJAlomarABieberTEuropean Dermatology Forum (EDF)European Academy of Dermatology and Venereology (EADV)European Federation of Allergy (EFA)European Task Force on Atopic Dermatitis (ETFAD)European Society of Pediatric Dermatology (ESPD)Global Allergy and Asthma European Network (GA2LEN)Guidelines for treatment of atopic eczema (atopic dermatitis) part IJ Eur Acad Dermatol Venereol2012268 1045 106022805051
   PubMed Web of Science ®Google Scholar
• RingJAlomarABieberTEuropean Dermatology ForumEuropean Academy of Dermatology and VenereologyEuropean Task Force on Atopic DermatitisEuropean Federation of AllergyEuropean Society of Pediatric DermatologyGlobal Allergy and Asthma European NetworkGuidelines for treatment of atopic eczema (atopic dermatitis) Part IIJ Eur Acad Dermatol Venereol2012269 1176 119322813359
   PubMed Web of Science ®Google Scholar
• D’ErmeAMHohlDUse of emollient in atopic dermatitis preventionDermatol Ther2016294 286 28726950266
   PubMed Web of Science ®Google Scholar
• McGregorSFarhangianMEFeldmanSRDupilumab for the treatment of atopic dermatitis: a clinical trial reviewExpert Opin Biol Ther20151511 1657 1660
   PubMed Web of Science ®Google Scholar
• NotaroERSidburyRSystemic agents for severe atopic dermatitis in childrenPaediatr Drugs2015176 449 45726547214
   PubMed Web of Science ®Google Scholar
• BiedermannTWerfelTStatus quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portasHautarzt2015662 108 11325645542
   PubMed Web of Science ®Google Scholar
• D’ErmeAMThe beginning of biological treatment era in the atopic dermatitis managementDermatol Ther2016293 208 20926331894
   PubMed Web of Science ®Google Scholar
• LaufferFRingJTarget-oriented therapy: emerging drugs for atopic dermatitisExpert Opin Emerg Drugs2016211 81 8926808004
   PubMed Web of Science ®Google Scholar
• WangHHLiYCHuangYCEfficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysisJ Allergy Clin Immunol20161386 1719 1722.e127543070
   PubMed Web of Science ®Google Scholar
• OldhoffJMDarsowUWerfelTAnti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitisAllergy2005605 693 69615813818
   PubMed Web of Science ®Google Scholar
• BlakelyKGooderhamMPappKDupilumab, a monoclonal antibody for atopic dermatitis: a review of current literatureSkin Therapy Lett2016212 1 5
   PubMedGoogle Scholar
• KovalenkoPDiCioccioATDavisJDExploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteersCPT Pharmacometrics Syst Pharmacol2016511 617 62427778477
   PubMedGoogle Scholar
• HamiltonJDSuárez-FariñasMDhingraNDupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJ Allergy Clin Immunol20141346 1293 130025482871
   PubMed Web of Science ®Google Scholar
• BeckLAThaçiDHamiltonJDDupilumab treatment in adults with moderate-to-severe atopic dermatitisN Engl J Med20143712 130 13925006719
   PubMed Web of Science ®Google Scholar
• ThaçiDSimpsonELBeckLAEfficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialLancet201638710013 40 5226454361
   PubMed Web of Science ®Google Scholar
• SimpsonELGadkariAWormMDupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)J Am Acad Dermatol2016753 506 51527268421
   PubMed Web of Science ®Google Scholar
• WollenbergABieberTProactive therapy of atopic dermatitis – an emerging conceptAllergy2009642 276 27819076538
   PubMed Web of Science ®Google Scholar
• HamiltonJDUngarBGuttman-YasskyEDrug evaluation review: dupilumab in atopic dermatitisImmunotherapy2015710 1043 105826598956
   PubMed Web of Science ®Google Scholar
• SimpsonELBieberTGuttman-YasskyESOLO 1 and SOLO 2 InvestigatorsTwo phase 3 trials of dupilumab versus placebo in atopic dermatitisN Engl J Med201637524 2335 234827690741
   PubMed Web of Science ®Google Scholar
• SantiniGMoresNMalerbaMDupilumab for the treatment of asthmaExpert Opin Investig Drugs2017263 357 366
   PubMed Web of Science ®Google Scholar
• OzdemirCMonoclonal antibodies in allergy; updated applications and promising trialsRecent Pat Inflamm Allergy Drug Discov201591 54 6525706526
   PubMedGoogle Scholar